Search reports, ask a question, or jump to a page.
The problem
Intervention: Administration of measles-rubella vaccine at six months of age, compared to standard nine-month timing, with booster doses at varying intervals (12 or 18 months)
Who it was tested with: Ugandan infants aged 24-28 weeks at enrolment (n=450), stratified by maternal HIV status and baseline haemoglobin level.
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"Infants aged 24-28 weeks were randomly assigned to receive MR at six and 12 months (group A), nine and 18 months (group B) or six and 18 months (group C). Infants were electronically randomised in a 1:1:1 ratio using block randomisation of varying sizes, stratified by site, maternal HIV status and baseline haemoglobin level." The randomised comparison of early versus standard vaccination timing with measurement of safety outcomes across groups provides experimental evidence for the safety profile of early measles vaccination.
Preliminary safety data only; open-label design without blinding may introduce bias; incomplete efficacy data; limited to Ugandan setting and may not generalise to other populations; causality of adverse events not definitively established for all cases
Across countries and designs
5 studies · 3 countries
